Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in the liver, increase T lymphocyte infiltration, and consequently improve the postoperative prognosis for patients with surgically resectable colorectal cancer liver metastases (RAS/BRAF wild-type, pMMR/MSS) compared to FOLFOX alone.

Trial Details

NCT ID
NCT06280495
Phase
PHASE2 / PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Oxaliplatin
  • Fluorouracil
  • Serplulimab
  • Bevacizumab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age ≥18 and ≤75 years old
  • Histologically confirmed colorectal adenocarcinoma
  • Radiological and/or pathological confirmation of liver metastases, with ≤5 lesions
  • Genetic testing and/or immunohistochemistry confirmation of RAS, BRAF wild-type, and pMMR/MSS

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →